CN102641431B - Medicament for treating vitreous opacity - Google Patents

Medicament for treating vitreous opacity Download PDF

Info

Publication number
CN102641431B
CN102641431B CN 201210158181 CN201210158181A CN102641431B CN 102641431 B CN102641431 B CN 102641431B CN 201210158181 CN201210158181 CN 201210158181 CN 201210158181 A CN201210158181 A CN 201210158181A CN 102641431 B CN102641431 B CN 102641431B
Authority
CN
China
Prior art keywords
parts
vitreous opacity
chinese
medicament
herba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 201210158181
Other languages
Chinese (zh)
Other versions
CN102641431A (en
Inventor
修方伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nantong Hongci Pharmaceutical Co Ltd
Original Assignee
修方伟
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 修方伟 filed Critical 修方伟
Priority to CN 201210158181 priority Critical patent/CN102641431B/en
Publication of CN102641431A publication Critical patent/CN102641431A/en
Application granted granted Critical
Publication of CN102641431B publication Critical patent/CN102641431B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention discloses a medicament for treating vitreous opacity, which can solve the treatment problem of vitreous opacity. The medicament is characterized by being processed from a variety of traditional Chinese medicines, and the formula comprises the following raw materials in parts by weight: 6-10 parts of nostoc sphaeroids kutz, 8-15 parts of Chinese angelica, 8-15 parts of dendrobium, 6-10 parts of Chinese trumpet creeper, 6-10 parts of feather cockscomb seed, 8-15 parts of radix rehmanniae preparata, 6-10 parts of white paeony root, 8-15 parts of Chinese taxillus twig and 3-6 parts of Chinese usnea. Clinical experiments prove that the medicament disclosed by the invention has the characteristics of good curative effect and higher safety for treating vitreous opacity and is worthy of clinical application and popularization.

Description

A kind of medicine for the treatment of vitreous opacity
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to treat the medicine of vitreous opacity.
Background technology
The normal glass body is a transparent gelinite, increase with the age has the tendency that degeneration takes place, and mainly shows as condensing and liquefaction, also is that opaque body appears in transparent gelinite in the vitreous body, being called vitreous opacity (vitreous opacities), is the ophthalmology common disease of middle-aged and elderly people.Its symptom shows as the visual field and column of smoke shape or cloud form shadow occur, and vitreous body is dirt shape, thread, cotton-shaped, streak muddiness.Vitreous opacity is not a kind of independently disease, but the common performance of many oculopathy, this disease develops rapidly sometimes, and patient's vision is dropped rapidly to light sensation, brings huge misery and inconvenience to life.In addition, vitreous body itself had not only had blood vessel but also impassivity, and metabolism is very slow, and when muddiness occurred, often therapeutic effect was not good enough.For severe vitreous hemorrhage patient, can only adopt the therapeutic modality of vitreous excision, but complication is more and easily lose vision.
Summary of the invention
Technical assignment of the present invention is at above the deficiencies in the prior art, and the medicine of the sure treatment vitreous opacity of a kind of curative effect is provided.
The technical scheme that the present invention solves its technical problem is: a kind of medicine for the treatment of vitreous opacity, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 6 ~ 10 parts of Nostoc, 8 ~ 15 parts of Radix Angelicae Sinensis, 8 ~ 15 parts of Herba Dendrobiis, 6 ~ 10 parts of Fructus Solani Lyratis, 6 ~ 10 parts of Semen Celosiae, 8 ~ 15 parts in Radix Rehmanniae Preparata, 6 ~ 10 parts of the Radix Paeoniae Albas, 8 ~ 15 parts of Herba Taxillis, 3 ~ 6 parts of Usneas.
Its optimum weight proportioning is: 8 parts of Nostoc, 10 parts of Radix Angelicae Sinensis, 10 parts of Herba Dendrobiis, 8 parts of Fructus Solani Lyratis, 8 parts of Semen Celosiae, 10 parts in Radix Rehmanniae Preparata, 8 parts of the Radix Paeoniae Albas, 10 parts of Herba Taxillis, 5 parts of Usneas.
Wherein said: Nostoc is algae Cyanophyceae nostocaceae nostoc beads algae Nostoc commune Vauch..Nature and flavor are light, and are cold.Return liver, heart channel.But the merit heat clearing away, convergence, QI invigorating makes eye bright.
Radix Angelicae Sinensis is the dry root of umbelliferae angelica Angelica sinensis (Oliv.) Diels.Nature and flavor are sweet, hot, temperature.Return liver, the heart, spleen channel.Merit can be enriched blood and be invigorated blood circulation, menstruction regulating and pain relieving, loosening bowel to relieve constipation.
Herba Dendrobii is orchid dendrobium loddigesii Rolfe Dendrobium loddigesii Rolfe., Herba Dendrobii oculati Dendrobium fimbriatum Hook. var. oculatum Hook., the fresh or dry stem of HERBA DENDROBII Dendrobium chrysanthum Wall., Herba Dendrobii Dendrobium candidum Wall. ex Lindl. or Dendrobium nobile Dendrobium nobile Lindl..Nature and flavor are sweet, are slightly cold.Return stomach, kidney channel.But the merit reinforcing stomach reg fluid, nourishing YIN and clearing away heat.
Fructus Solani Lyrati is the fruit of plant of Solanaceae Herba Solani Lyrati Solanum lyratum Thunb..Sour in the mouth; Property is put down.The merit materials for improving vision; Pain relieving.
Semen Celosiae is the dry mature seed of amaranthaceous plant Herba Celosiae argenteae Celosia argentea L..The nature and flavor hardship is slightly cold.Return Liver Channel.But the merit liver heat removing makes eye bright, nebula removing.
Radix Rehmanniae Preparata is concocted through processing for the tuber of scrophulariaceae rehmannia glutinosa plant Rehmannia glutinosa Libosch. and to be formed.Sweet in the mouth; Warm in nature.Return liver, kidney channel.Merit can be enriched blood moist; The benefit essence is filled out marrow.
The Radix Paeoniae Alba is the dry root of ranunculaceae plant Radix Paeoniae Paeonia lactiflora Pall..Nature and flavor hardship, acid are slightly cold.Return liver, spleen channel.But the pain relieving of merit suppressing the hyperactive liver, nourishing blood for regulating menstruation, astringing YIN to stop sweating.
Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser.Nature and flavor hardship, sweet, flat.Return liver, kidney channel.But the merit invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Usnea is the thallus (thallus) of Usneaceae Usnea plant USNEA Usnea diffracta (women trailing plants, Herba Cucubali) Usnea diffracta Vain. or Usnea Longissima (Scolopendra Usnea, Herba Stellariae Alsines) U. longissima Ach..Nature and flavor are sweet, and are flat.But the merit heat-clearing and toxic substances removing, hemostasia and promoting granulation, pain relieving, liver heat removing and eyesight improving moves back nebula.
Composition principle: the described vitreous opacity of modern medicine, often by tunica uvea, amphiblestroid inflammation, hemorrhage, regression, and Vitrea regression etc. causes, the vitreous opacity that is equivalent to the traditional medicine record, so-called vitreous opacity refers to that an outward appearance end is good, only conscious seemingly have mosquitos and flies or cloud and mist sample shadow to dance in the air drift at the moment, even the oculopathy of poor vision." silver-colored Nereid is little " is referred to as the black flower of fly wing." Standards of Diagnosis and Treatment miscellaneous diseases seven apertures door " beginning claims vitreous opacity.Its pathological changes of primary disease is at refreshing cream, and mainly by general on the asthenic fire, blood stasis is stagnated or deficiency of both the liver and kidney, due to the asthenia of essence and blood, so eliminating evilly should stagnate and set about from clearind deficient heat, repercussive; Setting upright should be based on invigorating the liver and kidney, foster essence and blood.Nostoc is returned liver, heart channel, but the heat clearing away QI invigorating make eye bright, Fructus Solani Lyrati makes eye bright, Semen Celosiae, Usnea liver heat removing and eyesight improving nebula removing, more than all medicines go into from eliminating evil; Chinese angelica blood supplementing is invigorated blood circulation, and Radix Paeoniae Alba suppressing the hyperactive liver nourishes blood, the Herba Taxilli invigorating the liver and kidney, the Radix Rehmanniae Preparata enriching blood and replenishing vital essence is filled out marrow, the Herba Dendrobii nourishing YIN and clearing away heat, more than all medicines from set upright into.All medicines share, and play the effect that benefiting QI and nourishing blood, liver heat removing and eyesight improving, easing the affected liver the kidney invigorating, beneficial essence are filled out marrow altogether, have promoted local blood circulation, can alleviate the vitreous opacity symptom.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Nostoc 6g, Radix Angelicae Sinensis 8g, Herba Dendrobii 8g, Fructus Solani Lyrati 6g, Semen Celosiae 6g, Radix Rehmanniae Preparata 8g, Radix Paeoniae Alba 6g, Herba Taxilli 8g, Usnea 3g.
Embodiment 2, the crude drug weight proportion: Nostoc 10g, Radix Angelicae Sinensis 15g, Herba Dendrobii 15g, Fructus Solani Lyrati 10g, Semen Celosiae 10g, Radix Rehmanniae Preparata 15g, Radix Paeoniae Alba 10g, Herba Taxilli 15g, Usnea 6g.
Embodiment 3, the crude drug weight proportion: Nostoc 8g, Radix Angelicae Sinensis 10g, Herba Dendrobii 10g, Fructus Solani Lyrati 8g, Semen Celosiae 8g, Radix Rehmanniae Preparata 10g, Radix Paeoniae Alba 8g, Herba Taxilli 10g, Usnea 5g.
During use, Chinese medicine Nostoc of the present invention, Radix Angelicae Sinensis, Herba Dendrobii, Fructus Solani Lyrati, Semen Celosiae, Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Usnea and Herba Taxilli are decocted with water twice, merging filtrate divides and sooner or later takes.
Effective combination of said medicine is coordinated mutually, can effectively reach the purpose for the treatment of vitreous opacity, and side effect is less.The above results is that clinical data proves that fully interrelated data is as follows, wherein studies drug use and is the crude drug weight proportion among the embodiment 3.
1 object and method.
1.1 the patient of the vitreous opacity that object in January, 2009 ~ 2011 year JIUYUE 90 examples (133 eyes) a variety of causes causes.Male 31 examples wherein, women 21 examples, 26 ~ 79 years old age.The cause of disease of vitreous opacity takes place: 47 of traumatic hematocele 33 examples, 40 of hemorrhage 29 examples of diabetic, 39 of hypertension retinopathy 21 examples, 7 of moderate and high myopia 7 examples.
1.2 method.
1.2.1 grouping is divided into two groups at random, matched group 46 examples (62 eyes) and treatment are organized 44 examples (71 eyes) and are observed contrast.Patient's age, sex, eye Gou Cheng not gone up no significance difference between two groups.
1.2.2 the Therapeutic Method matched group adopts 0.9% normal saline solution or 5% glucose injection 250ml to add cyclonamine injection 1.0g, vitamin C injection 3.0g, dexamethasone injection 5mg intravenous drip, bright, each the 1ml associating intramuscular injection of prolonium iodide of eye.Every day 1 time, 7 days is 1 course for the treatment of, continuous 4 courses for the treatment of; Dexamethasone changes prednisone 20mg into after first course for the treatment of, at 8 o'clock in morning every day is oral, more gradually decrement to stopping.Treatment group data scheme is that to add the embodiment of the invention 3 gained Chinese medicine decoction on the matched group basis more oral, and every day 1 time, 7 days is 1 course for the treatment of, continuous 4 courses for the treatment of.
1.2.3 capable slit lamp, ophthalmofundoscope and examination of visual acuity respectively before the observation index treatment, behind treatment 14d, the 28d, observe the curative effect difference is by ultrasound diagnosis vitreous opacity absorbing state.Vitreous opacity is by standard level Four point-score: the I level: vitreous opacity but do not influence fundus observation; The II level: the optical fundus reflection to red light is obvious, can dimly get a glimpse of optic disc and blood vessel; The III level: there is reflection to red light on the optical fundus, cannot see optical fundus blood vessel; The IV level: lesser ring of Merkel does not have reflection to red light.
1.2.4 curative effect determinate standard: efficacy evaluation with reference to mydriasis after directly ophthalmofundoscopy result and examination of visual acuity result.Produce effects: vitreous opacity obviously absorbs, and primary affection is controlled, transference cure, vision improves more than 5 row, vitreous opacity by the IV level to the II level, to the I level, high-visible to the optical fundus by the II level restoration by the III level; Effectively: vitreous opacity partially absorbs, sx, vision improves 2 ~ 5 row, vitreous opacity by the IV level to the III level, by the III level to the II level; Invalid: vitreous opacity no change or increase the weight of, symptom does not have improvement, and vision does not have raising.
1.2.5 statistical analysis carries out statistical analysis with SPSS 13.0, P<0.05 expression has the significance meaning.
2 results: the curative effect of two groups of cases relatively sees the following form, and obvious effective rate and total effective rate treatment group obviously are better than matched group (P<0.05).
Figure 165219DEST_PATH_IMAGE002
3. conclusion: this result of study shows that the present invention treats the vitreous opacity determined curative effect, is worthy of promotion and application, and especially to basic hospital, does not have certain device and technical merit, also has those to fear operation, the more worth application of surgical contraindication patient is arranged.

Claims (2)

1. medicine for the treatment of vitreous opacity, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 6 ~ 10 parts of Nostoc, 8 ~ 15 parts of Radix Angelicae Sinensis, 8 ~ 15 parts of Herba Dendrobiis, 6 ~ 10 parts of Fructus Solani Lyratis, 6 ~ 10 parts of Semen Celosiae, 8 ~ 15 parts in Radix Rehmanniae Preparata, 6 ~ 10 parts of the Radix Paeoniae Albas, 8 ~ 15 parts of Herba Taxillis, 3 ~ 6 parts of Usneas.
2. a kind of medicine for the treatment of vitreous opacity according to claim 1 is characterized in that its weight proportion is: 8 parts of Nostoc, 10 parts of Radix Angelicae Sinensis, 10 parts of Herba Dendrobiis, 8 parts of Fructus Solani Lyratis, 8 parts of Semen Celosiae, 10 parts in Radix Rehmanniae Preparata, 8 parts of the Radix Paeoniae Albas, 10 parts of Herba Taxillis, 5 parts of Usneas.
CN 201210158181 2012-05-21 2012-05-21 Medicament for treating vitreous opacity Expired - Fee Related CN102641431B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210158181 CN102641431B (en) 2012-05-21 2012-05-21 Medicament for treating vitreous opacity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210158181 CN102641431B (en) 2012-05-21 2012-05-21 Medicament for treating vitreous opacity

Publications (2)

Publication Number Publication Date
CN102641431A CN102641431A (en) 2012-08-22
CN102641431B true CN102641431B (en) 2013-07-10

Family

ID=46654675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210158181 Expired - Fee Related CN102641431B (en) 2012-05-21 2012-05-21 Medicament for treating vitreous opacity

Country Status (1)

Country Link
CN (1) CN102641431B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238213A (en) * 1999-04-16 1999-12-15 陈李林 Medicinal capsules for improving vision and its preparing method
CN1362124A (en) * 2001-01-04 2002-08-07 杨孟君 Nano eyesight-improving noble dendrobium medicine and its preparation
US20050058730A1 (en) * 2003-09-15 2005-03-17 Xushan Wan Compositions and methods for preventing or treating eyestrain
CN1634195A (en) * 2003-12-30 2005-07-06 吉林省第二荣复军人医院 Eye disease treating medicine
CN101972340A (en) * 2010-10-08 2011-02-16 张继成 Traditional Chinese medicine composition for tonifying liver and improving eyesight

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1238213A (en) * 1999-04-16 1999-12-15 陈李林 Medicinal capsules for improving vision and its preparing method
CN1362124A (en) * 2001-01-04 2002-08-07 杨孟君 Nano eyesight-improving noble dendrobium medicine and its preparation
US20050058730A1 (en) * 2003-09-15 2005-03-17 Xushan Wan Compositions and methods for preventing or treating eyestrain
CN1634195A (en) * 2003-12-30 2005-07-06 吉林省第二荣复军人医院 Eye disease treating medicine
CN101972340A (en) * 2010-10-08 2011-02-16 张继成 Traditional Chinese medicine composition for tonifying liver and improving eyesight

Also Published As

Publication number Publication date
CN102641431A (en) 2012-08-22

Similar Documents

Publication Publication Date Title
CN102139030B (en) Oral Chinese herbal preparation for treating gingivitis and preparation method thereof
CN102600386B (en) Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation
CN103393915B (en) Chinese medicinal preparation for treating xerophthalmia
CN1160091C (en) Medicine for treating ophthalmopathy
CN102641431B (en) Medicament for treating vitreous opacity
CN104435487A (en) Traditional Chinese medicine for treating hypertension complicated with diabetic fundi disease and preparation method thereof
CN102008627A (en) Traditional Chinese medicinal preparation for treating diabetic retinopathy
CN101612288B (en) Traditional Chinese medicine for treating diabetic retinopathy
CN106540170A (en) A kind of Chinese medicine for treating the bleeding eye diseases such as macular degeneration, retinal vein obstruction
CN104689079A (en) Traditional Chinese medicine composition for treating diabetic retinopathy and preparation method thereof
CN104096153A (en) Pharmaceutical composition containing multiple plant active ingredients and preparation method and application thereof
CN104491612A (en) Purpose of traditional Chinese medicine composition in preparing medicament for treating diabetic retinopathy
CN106668240A (en) Pharmaceutical composition for treating vitreous opacity
CN109464633A (en) A kind of application of Chinese medicine composition in the drug of preparation treatment softening hard masses Jie , lumps in the chest and abdomen
CN108938844A (en) Shegan Kangbingdu Injection by RP, preparation method and intravenously administrable Shegan Kangbingdu Injection by RP
CN105125848A (en) Traditional Chinese medicine for treating dry eye syndromes
CN1289609A (en) Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes
CN105250394A (en) Traditional Chinese medicine composition for treating cataract and preparation method and application thereof
CN104324139A (en) Medicine composition for treating xerophthalmia
CN1233360C (en) Chinese medicine preparation for treating hemorrhage of the ocular fundus vitreous opacity
CN104491403A (en) Medicine for treating central retinochoroiditis and preparation method
CN110841006A (en) A topical Chinese medicinal composition for treating myopia, and its preparation method
CN109954054A (en) Shegan Kangbingdu Injection by RP, preparation method and intravenously administrable Shegan Kangbingdu Injection by RP
CN101129837A (en) Proprietary Chinese medicine for treating retina affection of diabetes
CN110101799A (en) A kind of tea bag and preparation method thereof for treating xerophthalmia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: NANTONG HONGCI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: XIU FANGWEI

Effective date: 20140911

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 276826 RIZHAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20140911

Address after: 226200 chemical industry park, Nantong, Jiangsu, Qidong

Patentee after: NANTONG HONGCI PHARMACEUTICAL CO., LTD.

Address before: 276826 Rizhao People's Hospital, 126 Tai'an Road, Shandong, Rizhao City, China

Patentee before: Xiu Fangwei

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20180521